Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving ...

SELLAS Life Sciences Group, Inc. announced promising preclinical results for SLS009 (tambiciclib) in treating ASXL1 mutated colorectal cancer, highlighted at the 2025 ASCO Annual Meeting. In studies, ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis—a ...

SELLAS Life Sciences Group, Inc. announced plans to present preclinical data on the efficacy of its cancer therapy SLS009 (tambiciclib) at the upcoming ASCO Annual Meeting, scheduled for May 30 to ...

The MarketWatch News Department was not involved in the creation of this content. IMT-380 induces selective depletion of pathogenic CD161+ T cells, reducing inflammatory cytokine expression across in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sail Biomedicines, a Flagship Pioneering company and leader in RNA-based programmable medicines, today announced that it will present new preclinical data from its ...

FOG-001, the first and only direct β-catenin:TCF inhibitor, shows early clinical activity in a range of Wnt/β-catenin–driven tumors — reinforcing clinical development opportunities across both rare ...

KING OF PRUSSIA, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs, a subsidiary of SK Biopharmaceuticals, Co., Ltd., a global biotech focused on the research, development, and ...

FOG-001, the first and only direct β-catenin:TCF inhibitor, shows early clinical activity in a range of Wnt/β-catenin–driven tumors — reinforcing clinical development opportunities across both rare ...